Cue Biopharma Inc

Cue Biopharma Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.09
  • Today's Change0.05 / 1.64%
  • Shares traded167.10k
  • 1 Year change-44.62%
  • Beta1.9688
Data delayed at least 15 minutes, as of Mar 20 2023 20:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

  • Revenue in USD (TTM)9.35m
  • Net income in USD-46.80m
  • Incorporated2014
  • Employees57.00
  • Location
    Cue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
  • Phone+1 (617) 949-2680
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cuebiopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Inotiv Inc586.20m-341.29m119.19m2.10k--0.424--0.2033-13.33-13.3322.9810.970.62537.648.00279,275.40-36.35-35.01-41.73-44.4727.2229.67-58.13-,193.33--153.46--
CytomX Therapeutics Inc71.94m-97.59m122.92m174.00--4.31--1.71-1.49-1.491.100.43180.2407--55.36413,465.50-32.65-20.40-48.78-26.44-----135.65-103.79----0.00---30.6835.84-154.25---5.86--
Carisma Therapeutics Inc40.00m-19.88m125.59m17.00--4.00--3.14-0.0991-0.09910.19910.78020.1861--3.812,352,941.00-9.25-25.47-10.27-27.87-----49.71-236.32----0.00--50.69148.16-5,817.86------
ProPhase Labs Inc145.98m31.50m125.83m129.005.251.823.450.8621.471.476.744.241.719.246.021,131,628.0036.95-0.785343.78-0.939357.5344.2521.58-0.92623.9247.390.1054--444.5979.80369.69--45.40--
Anixa Biosciences Inc0.00-13.60m126.17m4.00--4.34-----0.4478-0.44780.000.93960.00----0.00-41.31-80.77-42.45-85.60-------3,362.83----0.00---100.00---4.95------
Annovis Bio Inc0.00-28.15m126.62m3.00--4.23-----3.45-3.450.003.670.00----0.00-70.25---73.60--------------0.00-------165.23------
Personalis Inc65.05m-113.32m127.59m395.00--0.5845--1.96-2.48-2.481.424.670.18887.283.71164,676.00-32.88-26.39-36.27-33.8320.5229.81-174.20-79.725.77--0.0118---23.9247.26-73.73--57.44--
Veru Inc27.73m-114.24m129.05m233.00--2.63--4.65-1.42-1.420.34550.6090.2011.214.65119,000.00-82.80-30.72-102.95-37.9570.1573.21-412.01-68.791.60-115.310.1995---35.7623.58-1,232.97--40.58--
Cue Biopharma Inc9.35m-46.80m130.85m57.00--2.12--14.00-1.38-1.380.27631.430.1205--11.93164,006.50-60.32-56.36-72.23-65.49-----500.65-827.70----0.164--373.68--1.39--12.09--
RVL Pharmaceuticals PLC42.77m-53.05m130.88m156.00--1.91--3.06-0.6251-0.62570.50200.69130.322911.0415.39274,192.30-40.05-18.78-55.99-21.8681.3551.85-124.02-61.823.27-90.100.4493---90.16-39.64-4.10---35.47--
ESSA Pharma Inc0.00-32.75m130.95m50.00--0.8083-----0.7433-0.74330.003.670.00----0.00-18.37-27.41-18.72-28.52------------0.00------4.62------
Enzolytics Inc0.00-119.19k132.75m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
Shattuck Labs Inc652.00k-101.95m139.23m105.00--0.7893--213.55-2.41-2.410.01544.160.0026----6,209.52-40.46---44.87-------15,635.74------0.00---97.83---126.68------
Reneo Pharmaceuticals Inc0.00-48.96m140.06m32.00--1.25-----2.00-
Y-mAbs Therapeutics Inc43.42m-133.62m140.17m148.00--1.30--3.23-3.06-3.060.99352.470.22621.255.26293,364.90-69.61-44.96-81.84-49.5584.09---307.75-571.593.97--0.00--68.18--53.68------
Data as of Mar 20 2023. Currency figures normalised to Cue Biopharma Inc's reporting currency: US Dollar USD

Institutional shareholders

21.83%Per cent of shares held by top holders
HolderShares% Held
Slate Path Capital LPas of 31 Dec 20222.40m5.58%
Prosight Management LPas of 31 Dec 20221.84m4.28%
The Vanguard Group, Inc.as of 31 Dec 20221.52m3.53%
Bleichroeder LPas of 31 Dec 2022861.28k2.00%
BlackRock Fund Advisorsas of 31 Dec 2022602.62k1.40%
Monaco Asset Management SAMas of 31 Dec 2022497.18k1.16%
Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Dec 2022478.50k1.11%
Dimensional Fund Advisors LPas of 31 Dec 2022457.67k1.06%
Millennium Management LLCas of 31 Dec 2022373.98k0.87%
Carlson Capital LPas of 31 Dec 2022365.00k0.85%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.